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Background: Muscle loss and fat gain contribute to the disability, pain, and morbidity associated with knee osteoarthritis
(OA), and thigh muscle weakness is an independent and modifiable risk factor for it. However, while all published
treatment guidelines recommend muscle strengthening exercise to combat loss of muscle mass and strength in knee OA
patients, previous strength training studies either used intensities or loads below recommended levels for healthy adults
or were generally short, lasting only 6 to 24 weeks. The efficacy of high-intensity strength training in improving OA
symptoms, slowing progression, and affecting the underlying mechanisms has not been examined due to the
unsubstantiated belief that it might exacerbate symptoms. We hypothesize that in addition to short-term clinical benefits,
combining greater duration with high-intensity strength training will alter thigh composition sufficiently to attain
long-term reductions in knee-joint forces, lower pain levels, decrease inflammatory cytokines, and slow OA progression.
Methods/Design: This is an assessor-blind, randomized controlled trial. The study population consists of 372 older
(age ≥ 55 yrs) ambulatory, community-dwelling persons with: (1) mild-to-moderate medial tibiofemoral OA
(Kellgren-Lawrence (KL) = 2 or 3); (2) knee neutral or varus aligned knee ( -2° valgus ≤ angle ≤ 10° varus); (3) 20 kg.m-2 ≥
BMI ≤ 45 kg.m-2; and (3) no participation in a formal strength-training program for more than 30 minutes per week
within the past 6 months. Participants are randomized to one of 3 groups: high-intensity strength training (75-90%
1Repetition Maximum (1RM)); low-intensity strength training (30-40%1RM); or healthy living education. The primary
clinical aim is to compare the interventions’ effects on knee pain, and the primary mechanistic aim is to compare their
effects on knee-joint compressive forces during walking, a mechanism that affects the OA disease pathway. Secondary
aims will compare the interventions’ effects on additional clinical measures of disease severity (e.g., function, mobility);
disease progression measured by x-ray; thigh muscle and fat volume, measured by computed tomography (CT);
components of thigh muscle function, including hip abductor strength and quadriceps strength, and power; additional
measures of knee-joint loading; inflammatory and OA biomarkers; and health-related quality of life.
Discussion: Test-retest reliability for the thigh CT scan was: total thigh volume, intra-class correlation coefficients
(ICC) = 0.99; total fat volume, ICC = 0.99, and total muscle volume, ICC = 0.99. ICC for both isokinetic concentric knee
flexion and extension strength was 0.93, and for hip-abductor concentric strength was 0.99. The reliability of our 1RM
testing was: leg press, ICC = 0.95; leg curl, ICC = 0.99; and leg extension, ICC = 0.98. Results of this trial will provide
critically needed guidance for clinicians in a variety of health professions who prescribe and oversee treatment and
prevention of OA-related complications. Given the prevalence and impact of OA and the widespread availability of this
intervention, assessing the efficacy of optimal strength training has the potential for immediate and vital clinical impact.
Trial registration: ClinicalTrials.gov, NCT01489462* Correspondence: messier@wfu.edu
1Department of Health and Exercise Science, Wake Forest University,
Winston-Salem, NC 27109, USA
3Section on Gerontology and Geriatric Medicine, Wake Forest School of
Medicine, Winston-Salem, NC, USA
Full list of author information is available at the end of the article
© 2013 Messier et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Messier et al. BMC Musculoskeletal Disorders 2013, 14:208 Page 2 of 15
http://www.biomedcentral.com/1471-2474/14/208Background
By 2030, an estimated 67 million American adults will
report physician-diagnosed arthritis—a 40% increase in
25 years [1]. Osteoarthritis (OA) is the most common form
of arthritis and the leading cause of disability among adults;
the prevalence of self-reported doctor diagnosed OA in the
United States is estimated at greater than 27 million per-
sons [2]. Knee OA accounts for a significant portion of this
disability, and is largely due to factors that alter knee-joint
loading. Results from this project will inform future man-
agement of patients suffering from knee OA and could
have enormous public health implications.
Muscle loss and fat gain contribute to the disability, pain,
and morbidity associated with knee OA [3], and thigh
muscle weakness is an independent, modifiable risk factor
[4,5]. While treatment guidelines recommend strengthen-
ing exercise to combat sarcopenia in knee OA patients
[6,7], the appropriate intensities or loads (defined as per-
cent of one repetition maximum, or %1RM) recommended
are unclear. The intensities used in previous OA studies
were below those recommended by the American College
of Sports Medicine for healthy adults [8] (60-80% 1RM).
Further, the programs were generally short, between 6 and
24 weeks [9-16]; effect sizes were low-to-modest, changes
in progression could not be detected, and they provided
little lasting clinical benefit. Indeed, short-term exercise
benefits are gone 6 months post-exercise [17-19] but long-
term supervised exercise results in sustained benefits
2 years after the treatment ends [20]. Few have studied the
effectiveness of more intense strength training due to the
unsubstantiated belief that it might exacerbate OA symp-
toms [21]. Preliminary studies indicate that high-intensity
strength training is safe and well tolerated by healthy older
adults [22,23] and knee OA patients [16,24].
Greater thigh fat is associated with obesity, a major
risk factor for knee OA [25]. Obesity combined with
sarcopenia, termed sarcopenic obesity, is also closely as-
sociated with the prevalence of knee OA with an Odds
Ratio = 3.51 [26]. Intensive strength training can change
thigh composition in older adults and has shown prom-
ise in treating the underlying biomechanical (knee-joint
loading) and inflammatory disease pathways. Studies in
healthy older adults associate intensive strength training
with increased fat-free thigh mass and quadriceps cross-
sectional area and decreased percent body fat and thigh
subcutaneous fat with minimal alteration in total body
weight [27-30]. Sipila and Suominen [27] and Ferri et al.
[23] noted increased quadriceps cross-sectional area and
lean cross-sectional area, and less intramuscular thigh fat
after 16–18 weeks of intensive strength training. Simi-
larly, Treuth et al. [31-33] found increased thigh muscle
mass and decreased thigh fat mass after 16 weeks of
high-intensity strength training in older men and women.
High-intensity strength training also reduced interleukin(IL)-18, a pro-inflammatory cytokine, in HIV-infected pa-
tients [34] and IL-6 and C-reactive protein (CRP) levels in
older adults with chronic kidney disease compared to con-
trols [35]. We must now gather clinical and mechanistic
evidence to determine if improved thigh muscle compos-
ition has long-term protective effects on joint mechanics, in-
flammation, and structural progression in knee OA.
This paper describes the design of the Strength Training
for ARthritis Trial (START), the first long-term clinical
trial comparing the efficacy of high- (75-90% 1RM) to
low-intensity (30-40% 1RM) strength training and Healthy
Living Education interventions in older adults with knee
OA. This trial is designed to identify potential mechanisms,
(i.e. knee joint loading and systemic inflammation) re-
sponsible for any changes in pain, function, and mobility
consequent to intensive strength training. We expect ini-
tial improvements in thigh muscle function, pain, and
knee-joint loading with high-intensity strength training
after 6 months; 18 months will determine, for the first
time, if further changes in thigh muscle function and
composition significantly reduce knee-joint forces and
inflammatory cytokines resulting in a greater decrease in
pain and attenuated OA disease progression (Figure 1).
Given the prevalence of OA, the detrimental effects of
sarcopenia and obesity [26], and the safety and widespread
availability of the intervention, this trial has immediate, po-
tentially transformative clinical impact.
Methods/Design
Study design
START is an assessor-blinded, single-center, 18-month,
parallel design randomized controlled trial. Participants are
randomized into one of 3 groups: high-intensity strength
training (H), low-intensity strength training (L), or healthy
living education (C).
Study sample
The study sample consists of 372 ambulatory, community-
dwelling adults age ≥55 yrs with self-reported disability
due to knee OA. Inclusion criteria include: (1) mild-to-
moderate radiographic medial tibiofemoral OA (Kellgren-
Lawrence (KL) = 2 or 3); (2) knee neutral or varus aligned
knee ( -2° valgus ≤ angle ≤ 10° varus); (3) BMI ≥ 20 kg.m-2
and ≤ 45 kg.m-2; and (4) no participation in formal strength
training for more than 30 min.wk-1 in the past 6 months.
We exclude people with BMI >45 kg.m-2 because of
difficulty in using CT equipment and lower adherence to
exercise [36,37] and <20 kg.m-2 because of limited thigh
fat. We include only people with neutral (−2° valgus to
2° varus) or moderate varus (≤ 10° varus) alignment and
medial knee OA and not predominant lateral compartment
or severe patellofemoral (PF) compartment disease because
(1) the medial compartment is the most common dis-
ease site, and (2) medial progression is strongly associated
High Intensity Strength Training
Initial Improvement Thigh Composition 
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Greater Improvement Thigh Composition
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Figure 1 Hypothesized pathways mediating high-intensity strength-training outcomes at 6 and 18 mos.
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BMI [41]. People with extreme malalignment (>10 degrees
varus) might experience greater progression in a strength-
ening program [21,42]. Medial bone-marrow lesions are
seen mostly in patients with varus limbs, who are most
likely to progress medially [43]. This approach will engage
an enriched cohort of structural progressors to determine
better our intervention’s ability to slow the disease [16]. All
participants may maintain their medications, including
NSAIDs. If pain decreases, they may reduce them with
their physician’s consent. Medication use is recorded at
baseline and 6-, 12-, and 18-month follow-up testing. Ex-
clusion criteria are listed in Table 1. The study protocol
was reviewed and approved by the Human Subjects Com-
mittee of Wake Forest University Health Sciences (Human
Protocol: IRB00018176) and is in compliance with the
terms and conditions set forth in the Helsinki Declar-
ation (http://www.wma.net/en/30publications/10policies/
b3/index.html). Informed consent will be obtained from
all study participants.
Interventions
Strength training
Both strength training interventions consist of a 5-min
warm-up, 40-min training, and 15-min cool-down. The
60-min sessions are conducted 3 times.wk-1 for 18 months
at the Wake Forest Clinical Research Center. Each group
session will include between 12–24 participants (1 to 2
waves) and will be supervised by two American College ofSports Medicine certified exercise interventionists and a
number of undergraduate interns. The first two sessions
introduce participants to proper techniques, and at the
third, 1-repetition max (1RM) tests determine the starting
resistance used for each exercise in the subsequent ses-
sions until the next assessment (detailed below). Intensity
(load) is defined as %1RM [8]. The reliability of our 1RM
testing for 12 older adults with knee OA tested twice one
week apart was: leg press, ICC = 0.95; leg curl, ICC = 0.99;
and leg extension, ICC = 0.98. Each exercise is performed
on a Nautilus resistance-training machine with 60–90 s of
rest between sets; 1RM is defined as the maximum weight
one can lift in a single repetition. Participants will keep a
session log of each resistance exercise, its weight setting,
and number of sets and repetitions achieved. Although
our hypotheses focus on the lower extremity, experience
indicates that participants want a well-rounded program.
Thus, for both groups the program includes 6 lower body
exercises with each leg exercised separately to prevent an
unequal distribution of load between the least affected
and most affected sides: hip abduction and adduction; leg
curl, extension, and press; and seated calf; and 4 upper
body and core exercises: compound row, vertical chest,
lower back, and abdomen. We use Nautilus machines
based on time, safety, and availability, but results will be
generalizable to most strength training methods. Partici-
pants perform a 5 minute warm-up on either the walk-
ing track or a stationary bicycle and, at the completion
of each strength training session, a 15 minute cool-down
Table 1 Exclusion criteria
Criteria Exclusion Method
Significant co-morbid disease that would threaten safety
or impair ability to participate in interventions or testing,
previous acute knee injury, bilateral severe tibiofemoral
OA, severe patellofemoral OA (JSN = 3 using OARSI atlas),
no definite medial tibiofemoral OA, severe obesity, low
weight.
Symptomatic or severe coronary artery disease;
severe HTN; active cancer other than skin cancer;
anemia; dementia; liver disease; COPD; peripheral
vascular disease; inability to walk without an
assistive device; blindness; type 1 diabetes; type 2
diabetes on thiazolidinedione agents; bilateral
severe medial tibiofemoral OA (KL = 4), no definite
medial tibiofemoral OA (KL = 0, 1), BMI < 20 or
> 45 kg.m-2
Medical history; physical exam;
PA and skyline knee x-ray; height
and weight.
OA disease location and alignment restrictions:
predominant knee OA other than medial tibiofemoral OA;
valgus, or extreme varus alignment.
Lateral tibiofemoral OA >medial tibiofemoral OA,
severe patellofemoral OA; valgus knee alignment
> 2°, or varus alignment > 10°
Knee PA and skyline view x-rays,
lower extremity long x-ray.
Excess alcohol use ≥ 21 drinks per week Questionnaire
Inability to finish 18-month study or unlikely to be
compliant
Lives > 50 miles from site or planning to leave
area ≥ 3 months during the next 18 months
Questionnaire, interview
Conditions that prohibit CT BMI > 45 kg.m-2 height and weight
Significant cognitive impairment diagnosis of dementia or a MoCA score <20 Medical history, MoCA
Low Pain Pain≤ 3 on a scale from 0-20 WOMAC
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exercises.
Participants who plan absences of >2 sessions use
Thera-Bands in a home-based program. Upon their re-
turn, interventionists determine the progression needed
to reach prior intensity.
Previous strength training trials with older adults pre-
dict small fluctuations in body weight (< 1 kg) as muscle
mass increases and fat mass decreases [44]. Interven-
tionists are alert to any substantial change (≥ 2 kg) and,
if necessary, the participant is referred to the medical
director.
High-intensity intervention (H)
The H group performs 3 sets of each exercise at 75-90%
of 1RM, within the intensity range necessary to maximize
muscular hypertrophy [8]. Each block has the following
structure and is repeated with training loads recalibrated to
each new 1RM:
Weeks 1–2. 3 sets by 8 reps. Intensity: 75% of 1RM
Weeks 3–4. 3 sets by 8 reps. Intensity: 80% of 1RM
Weeks 5–6. 3 sets by 6 reps. Intensity: 85% of 1RM
Weeks 7–8. 3 sets by 4 reps. Intensity: 90% of 1RM
Week 9. Taper. Alternate exercises and 1RM testing
Most participants have no difficulty progressing at
2-wk intervals, but variation is inevitable. Participants will
rate perceived exertion (RPE) at completion of each work-
out. On a 10-point Borg category ratio-RPE scale, the H
group should be working between 5 (hard)-8 (very hard),
and the L group between 2 (easy)-4 (somewhat hard) [45].
At the end of each block, we add taper periods—2 days
(Monday, Friday) of alternate exercises using Thera-Bands,separated by a 1RM testing day (Wednesday)—because the
use of Thera-Bands has been shown to increase perform-
ance in older women [46].
Low-intensity intervention (L)
The L group performs 3 sets of 15 repetitions at 30-40%
of 1RM using the exercises described above. Each
8-week block has the following structure:
Weeks 1–2. 3 sets by 15 reps. Intensity: 30% of 1RM.
Weeks 3–4. 3 sets by 15 reps. Intensity: 35% of 1RM.
Weeks 4–6. 3 sets by 15 reps. Intensity: 40% of 1RM.
Weeks 7–8. 3 sets by 15 reps. Intensity: 35% of 1RM.
Week 9. Taper week. Alternate exercises and 1RM testing
Repeat weeks 1–8 with training loads recalibrated to
each new 1RM.
The workloads for the H and L groups are equated
(Table 2).
Healthy living education
The control group is modeled after the Arthritis Diet
and Activity Promotion Trial’s (ADAPT) healthy lifestyle
comparison group [47], providing attention, social inter-
action, and health education. Participants attend 60-min
organized workshops bi-weekly for the first 6 months
and monthly thereafter. This arm aims to control for at-
tention from study staff and general levels of participant
time; to encourage recruitment, adherence and benefit;
and not to influence the primary outcomes directly: no
evidence suggests that health education alone will affect
pain or knee-joint loads during walking. The decision to
use a tapered schedule is based on careful consideration
of science, adherence, and expense. The control group is
Table 2 Sample workloads and total volume for high- and low-intensity interventions, assuming 1RM = 100 lbs
Intervention Sets/Repetitions/Intensity Volume
Low Intensity
Weeks 1-2 3 sets of 15 reps at 30% 1-RM 45 reps*30 lbs = 1350 lbs* 2 wks = 2700 lbs
Weeks 3-4 3 sets of 15 reps at 35% 1-RM 45 reps*35 lbs = 1575 lbs* 2 wks = 3150 lbs
Weeks 5-6 3 sets of 15 reps at 40% 1-RM 45 reps*40 lbs = 1800 lbs*2 wks = 3600 lbs
Weeks 7-8 3 sets of 15 reps at 35% 1-RM 45 reps*35 lbs = 1575 lbs* 2 wks = 3150 lbs
Weeks 1 thru 8 Total volume = 12600 lbs
High Intensity
Weeks 1-2 3 sets of 8 reps at 75% 1-RM 24 reps*75 lbs = 1800 lbs*2wks = 3600 lbs
Weeks 3-4 3 sets of 8 reps at 80% 1-RM 24 reps*80 lbs = 1920 lbs*2wks = 3840 lbs
Weeks 5-6 3 sets of 6 reps at 85% 1-RM 18 reps*85 lbs = 1530 lbs*2wks = 3060 lbs
Weeks 7-8 3 sets of 4 reps at 90% 1-RM 12 reps*90 lbs = 1080 lbs*2 wks =2160 lbs
Weeks 1 thru 8 Total volume = 12660 lbs
Low/High Ratio = 1.0
Total volume = total repetitions * intensity *resistance (assume 100 lbs).
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but reflects the way community health-education pro-
grams are typically offered and the observation that
older adults are less likely to attend more often.
Over the 18 months, interactive presentations cover
such topics as hearing loss, nutrition, managing medica-
tion, and sleep practices, and experts will give wide-
ranging lectures. An experiential component encourages
participants to seek more information about their health
and related practices. They are asked to complete home-
work, review topics, and engage in small group discus-
sions to increase their involvement in this study arm.
Each workshop ends with seated upper body stretching
to enhance adherence and increase perceived benefit
without directly affecting the knees or study outcomes.
Prior studies suggest older adults are less likely to par-
ticipate if they think any treatment group does not pro-
vide personal benefit.
Techniques to improve adherence and retention
Time-intensive behavioral studies require significant
commitment [47-49]. START’s design evolved from so-
cial cognitive theory (SCT), group dynamics, and over
22 years’ experience in randomized controlled trials:
our 18-month trials Fitness Arthritis and Seniors Trial
(FAST), ADAPT, and Intensive Diet and Exercise for
Arthritis (IDEA) had between 80%- 88% retention and
58-70% adherence. We estimate 80% retention and 65%
adherence rates over the intervention; adherence is cal-
culated by dividing the total number of sessions com-
pleted by the number scheduled.
START interventionists are trained by our health psych-
ologist in standardized behavioral techniques developed in
a SCT framework. They include frequent contact during
the intervention; positive feedback; incentives to reachattendance and performance goals; establishing personal
commitment to the project; and targeted mechanisms
for behavioral adherence, including self-efficacy, outcome
expectations, and self-regulatory skills. The importance of
regular attendance is emphasized with study participants
on an ongoing basis. Adherence data are reviewed regu-
larly to identify any participants who need additional re-
minders and/or counseling. Our toolbox approach, guided
by algorithms of common strategies and decision-making
processes, tailors the intervention to each participant’s
needs. For example, if a participant misses two consecu-
tive sessions and has no contact with the interventionist, a
phone session is scheduled. The interventionist assesses
participant study goals and barriers to participation. To-
gether, participant and interventionist develop a specific
plan. Collectively, these strategies increase social cognitive
mechanisms for regular participation and enhanced ad-
herence in all groups.
Trial conduct
Recruitment
The 30-month recruitment period is divided into 10 waves
of approximately 37 participants each, entering the study
at 3-month intervals. The predominant recruitment strat-
egy is newspaper advertisements. Other recruitment ef-
forts include mass mailings, presentations at local aging
service networks, senior centers, churches, radio, and on-
line advertising. Our Claude D. Pepper Older Americans
Independence Center recruitment core also has access to
a large database of older adults who have consented
to be contacted about participation in clinical trials. Spe-
cific strategies aim to maximize the number of African
Americans who qualify for, and are enrolled in, the study.
At biweekly meetings, all recruitment activities and the
number of participants randomized are reviewed.
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Screening and follow-up visits
Those who are eligible after prescreening (PSV) sign an
informed consent and attend 2 screenings (SV) and a
randomization visit (RV). All 372 participants are mea-
sured at baseline, 6-, 12-, and 18-month follow-ups (FU)
(Figure 2 and Table 3).Screening
The Eligibility Questionnaire addresses joint pain, physical
function, activity level, co-morbid diseases, willingness to
participate for 18 months, height and weight (to determine
BMI), caregiver status, status of significant others, and dis-
tance of home from the center (within 50-mile radius). A
study physician and a physician assistant perform routine
medical exams. A score of <20 on the Montreal CognitiveTelephone Interview: Eligib
Consent, Medication For
Pas
20, 45 
BMI  (kg.m-2) 
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MOCA
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PASE
CES-D 
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yes
no
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Waist/hip/thigh 
Circumference 
DXA 
yes 
Figure 2 Participant eligibility and screening flow chart.Assessment (MoCA) [50,51] will justify exclusion because
cognitively impaired persons may not be able to adhere to
the protocol; persons scoring >17 on the Center for Epide-
miologic Studies Depression scale (CES-D) [52] are evalu-
ated by the study physician, who determines eligibility.Western Ontario McMasters Universities Osteoarthritis Index
(WOMAC)
Self-reported pain (primary clinical outcome) and phys-
ical function are measured using the Likert version of
WOMAC [53]. The pain index assesses participants’ pain
on a scale, ranging from 0 (none) to 4 (extreme). The pain
subscale consists of 5 items and total scores can range
from 0–20, with higher scores indicating greater pain. This
instrument is recommended by the Osteoarthritis Research
Society International as the health status measure of choiceility Status, Medical History 
m, Ht, Wt, Brief Phys Exam
s ? 
Frontal Plane Knee Alignment 
-2o, 10o
Knee OA
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Table 3 Data-collection visits
Measurements PSV SV1 SV2 RV FU6 FU12 FU18
randomization x
informed consent x
eligibility questionnaire x
medical history xc x x x x
WOMAC x x x x x
PASE scale x x x x
MoCA x x x x
CES-D x x x x
SF-36 (general health, quality life) x x x x
Self Efficacy x x x x
6-min walk x x x x
Demographics x
Brief physical exam x
Medication Form x x x x
Knee A-P x-ray x x
Knee x-ray skyline view x
Full length lower extremity x-ray x
height xc x
weight xc x x x x
Waist/Hip circumference x x x x
DXA x x
CT scans: thigh x x
Biomarkers: blood x x
Biomarkers: urine x x x
Gait Analysis x x x
Muscle function tests: Power, Strength x x x x
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in orthopaedic and pharmacologic interventions [53,54].
The pain subscale will be used only as a screening tool dur-
ing SV1 (pain must be > 3). It will also be administered to
the eligible participants at SV2 and each scheduled follow-
up visit.
For physical function, the Likert version asks partici-
pants to indicate on the same scale from 0 (none) to 4
(extreme) the degree of difficulty experienced performing
activities of daily living in the last 48 hours due to knee
OA. Individual scores for the 17 items are totaled to gener-
ate a summary score that can range from 0–68, with higher
scores indicating poorer function.
Gait
The primary mechanistic outcome is maximal knee
compressive force; secondary outcomes include internal
knee abduction moment and AP shear force [55-59]. A
25-reflective marker set, 6-camera Motion Analysis System
(100 Hz), and 2, 6-channel force plates (AMTI, Newton,
MA. 1000 Hz) obtain 3D kinematic and kinetic gait data.
The former will be acquired using Cortex 3.0 software(Motion Analysis Corporation, Santa Rosa, CA) and a
Butterworth low-pass filter (6 Hz cutoff). For each partici-
pant, 3 successful trials are analyzed; i.e., within ±3.5% of
the participant’s freely chosen speed, and the entire foot
must contact the force plate in a visually normal stride.
Smoothed coordinate data, ground reaction, and gravita-
tional and inertial forces will inform an inverse dynamics
model to calculate 3D moments and forces at the hip,
knee, and ankle joints using Visual 3D Standard 4.0 clinical
gait analysis software (C-Motion, Germantown, MD).
These moments and forces will be used in the knee
model developed by DeVita et al. [60] for use in knee
OA subjects [58,59]. Model-predicted knee-compression
force was also a primary outcome in IDEA. Our test-
retest reliability intraclass correlations (ICC) for 21
knee OA patients with mean age 65.7 yrs (SD = 5.8)
were r = 0.86 for internal peak knee extensor moment,
r = 0.94 for internal peak abductor moment, and r = 0.95
for peak knee compressive force [61]. A detailed explan-
ation of our model can be found elsewhere [62].
Numerous biomechanical-neuromuscular models exist
that predict knee joint forces during locomotion. Many
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ening the confidence researchers have in these models
[63-65]. True biomechanical model validation is difficult
and most predicted results have not been compared to
measured knee joint forces, a gold standard for model
validation. Recently, Fregly et al. [66] have made avail-
able measured in vivo knee joint force data during walk-
ing along with all pertinent biomechanical data for the
purpose of validating biomechanical models predicting
knee joint loads. These data come from individuals with
instrumented knee joint prostheses and are available
through the website, https://simtk.org/home/kneeloads.
We used their biomechanical gait data as input for our
model to predict knee joint forces from five walking trials
and then compared our results to Fregly’s actual measured
values from the same subjects. Our predicted values were
highly similar to the measured values with the predicted
first and second maximum compressive forces within 7%
and 3% of the observed values, respectively (Figure 3).
Mobility
Our measure of mobility is 6-min walk distance, with a
3-month test-retest reliability of 0.86 [67].
Health-Related Quality of Life (HRQL)
The SF-36 [68] is the most widely used and carefully val-
idated measure of HRQL. It yields two broad summary
scores: physical health and mental health.
Body composition
Dual-energy x-ray absorptiometry (DXA) (GE Healthcare
iDXA Digital Densitometry) is used for measurements of
bone mineral density (BMD) and body tissue composition
including whole body changes in total fat (FM) and lean
(LM) mass [69-71]. Percent coefficients of variation (%CV)
are 1.2% for whole body FM; 0.5% for whole body LM;Figure 3 Comparison of peak knee compressive forces derived
from our musculoskeletal model (predicted) using Fregly et al.
data as input, and the measured value from an instrumented
prostheses (measured) of the same subjects.0.9% for whole body BMD; 1.2% for posterioranterior (PA)
spine BMD; and 0.9% for total hip BMD.
Thigh composition
A secondary outcome is the measurement of thigh skel-
etal muscle and adipose tissue using volumetric non-
contrast enhanced computer tomography (CT) (VCT
64, GE Healthcare Waukesha, WI). Participants will be
placed supine on the CT couch with their legs held in a
neutral position by dedicated Velcro straps. A calibration
phantom (Image Analysis, Columbia, KY) with known CT
densities for fat, water, and calcium is placed in the scan
fields of view (FOV) posterior to the legs. A 2-dimensional
topogram is obtained covering from the pelvis to the knees.
A single helical scan series is performed starting at the
femoral head and ending below the knee joint in the tibial
plateau. Technique for the scan includes: helical mode, 120
KV, 150 mAs, with reconstruction of both legs at 5 mm
slice thickness and 50 cm display field of view (DFOV).
Additional reconstructions are performed using the same
exposure to the participant to obtain sets of images using
thinner slices (1.25 mm and 0.625 mm) using both stand-
ard and bone kernels to optimize image quality. Each
femur has a set of high-resolution 30-cm dfov targets for
potential future analysis of cortical bone structure.
CT image analysis software and protocol
The topogram of the femur is measured from the greater
tuberosity of the femur to the inferior aspect of the medial
femoral condyle. This length is trisected, and the junction
between the proximal and mid-third is the landmark for
measurement. Measurements of right and left thigh com-
position are performed using the slices that start at the lo-
cation 25 mm above and the end 25 mm below this point,
providing a sampling length of 50 mm along the long axis
of the femur (e.g. head to foot). CT images are analyzed
(reader masked to treatment group) on a medical imaging
workstation with custom plugins to measure the volume of
the entire thigh, thigh musculature, and intermuscular
fat. Test-retest reliability on the thigh CT scans of a
quality control sample of START participants (n = 10)
re-analyzed an average of 3.7 months apart was: total
thigh volume, ICC = 0.99; total fat volume, ICC = 0.99,
and total muscle volume, ICC = 0.99.
Blood and urine sample collection
Blood samples (50 ml per visit) for assessing biomarkers
are collected via venipuncture at a specific time in the
morning at least 2 hours after rising and after a 10-hour
overnight fast at baseline and at 6- and 18-month assess-
ment visits. Urine samples (second am void, 20 ml per
visit) are collected in 250 ml specimen cups by each par-
ticipant for analysis of new and emerging OA biomarkers.
Serum, plasma, and urine are aliquoted and stored at -80°C
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the end of the study. Aliquots are also stored long-term to
test for promising new inflammatory and OA biomarkers
that may become available after the study.
Inflammatory markers
IL-6, tumor necrosis factor-alpha (TNFα), and soluble
TNF receptor 1 (sTNFR1) were chosen for their known
implication in OA [72-77]. They have been shown to
change with 1 year of moderate strength training [78]. IL-6
is our primary inflammation measure. All inflammatory
marker assays are performed in the WFSM ELISA Core
Laboratory. All samples are measured in duplicate, using
the average for analyses. Commercially available (R&D Sys-
tems, Minneapolis, MN) enzyme-linked immunosorbent
assay (ELISA) kits are used: high-sensitivity Quantikine®
for IL-6. In our laboratory, inter- and intra-assay coeffi-
cients of variation (CV) for IL-6 are 5.4% and 3.5%, re-
spectively; for TNFα, 11.8% and 6.2%, respectively; and
under 5% for the soluble receptor assays
OA Biomarkers
There is a lack of gold standard biomarkers for OA and
so the choice of biomarkers that will be measured will
be based on the most recent findings available at the
completion of the trial. Possible markers could include
serum COMP (AnaMar Medical, Uppsala, SW) and urine
markers of collagen degradation such as C2C-HUSA (Ibex
Technologies, Montreal, CN).
Muscle function tests
Strength Knee flexion/extension concentric strength is
assessed at baseline, 6, 12, and 18 months using a Humac
NORM isokinetic dynamometer (Computer Sports Medi-
cine Inc, Stoughton, MA) set to 30 deg.s-1. Strength test-
retest reliability for 10 participants tested twice in our lab,
7–10 days apart, had an ICC of 0.93 for both concentric
knee flexion and extension strength. Since we suggest that
intensive strength training can reduce knee-joint loads by
counterbalancing the external knee-adductor moment with
strong hip abductors, we also measure hip-abductor con-
centric strength at 30 deg.s-1 (ICC = 0.99). Knee strength is
measured with the participant in a seated position; hip ab-
ductor strength is measured in a side lying position.
Power The Nottingham power rig is used to measure bi-
lateral leg extensor power because it correlates well with
such functional measures as chair-rise, stair-climbing, and
walking speed in elderly subjects [79]. This measurement
is safe and acceptable for all age groups [79,80].
Medications
A questionnaire adapted from the Atherosclerosis Risk
In Communities (ARIC) [81] study and widely used infield research and our studies is designed to obtain infor-
mation (during SV1 and FU visits) about all prescription
and over-the-counter medicines and supplements used
during the 2 weeks prior to interview.
X-ray
Bilateral PA weight-bearing knee x-rays using a position-
ing device (SynaFlexer™, Synarc Inc., San Francisco, CA)
and the modified Lyon-Schuss technique [82] are used
to identify tibiofemoral (TF) OA and skyline views to
identify PF OA. The former is repeated at 18 months to
assess changes in joint-space width (JSW). Radiographs
are evaluated using the K-L score of 0–4 to assess dis-
ease severity as we have described and we include only
participants with a score of 2 or 3 in at least one knee
(KL score = 4 is acceptable in the contralateral knee). We
exclude people with severe PF OA (JSN = 3 on a 0–3
scale using the OARSI atlas) and control for severity
(none-to-moderate) in statistical analyses. We define med-
ial TF disease based on our previous definitions [83], and
participants with lateral > medial joint space narrowing
are excluded.
The knee PA protocol includes positioning the partici-
pant standing and facing the Bucky or cassette holder
with the x-ray beam centered on the joint line angulated
caudally 10 degrees. The x-ray is repeated at 5 and 15
degrees and the most acceptable image (based upon
alignment of the medial tibial plateau) is used for ana-
lysis. Criteria include good contrast/exposure, optimal
visualization of the articular surfaces with the floor of
the medial tibial plateau clearly delineated, and both
knee joints included and centered on the film.
To assess alignment, a full-length AP radiograph of
each lower extremity is obtained at baseline with partici-
pants positioned following Sharma et al. [84]. Mechan-
ical alignment is the measure of the angle formed by the
intersection of the lines connecting the centers of the
femoral head and intercondylar notch and the centers of
the ankle talus and tibial spines, with neutral angles
between 0-2° varus, varus knee angles >2° inward, and
valgus angles >0° outward. The range of eligible knee an-
gles is -2° valgus to 10° varus.
Disease progression is defined as change in x-ray med-
ial TF JSW. A physician, masked to treatment group,
measures JSW using automated computerized software.
The software automatically delineates the joint space
contour with the help of an edge-based algorithm. The
area of measurement of minimum JSW is defined by 2
vertical lines and 2 horizontal lines obtained by a single
click on the nonosteophytic outer edge of the medial
femoral condyle and a single click on the inner edge of
the medial tibial plateau close to the articular surface.
Within these landmarks, the delineation of the bone
edges of the medial femoral condyle and medial tibial
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matically obtained [85].
Additional questionnaires
Physical Activity Scale for the Elderly (PASE) [86], Center
for Epidemiologic Studies Depression Scale (CES-D) (92),
and a self-efficacy for adherence measure [87] are used to
assess physical activity, depression, and self-efficacy at
baseline and follow-up. The Montreal Cognitive Assess-
ment (MoCA) is used to measure cognitive functioning
at baseline; a score ≥ 20 is required for study inclusion.
The Digital Symbol Substitution Test (DSST) will be
used to measure cognitive functioning.
Adverse event collection and reporting
An adverse event (AE) is defined as any unfavorable and
unintended diagnosis, sign, symptom, or disease tempor-
arily associated with the study intervention, which may
or may not be related to the intervention. Non-serious
AEs will be reported by the study staff to the project
manager and principal investigator within 7 days of noti-
fication of the event. The study physician will review
each non serious AE on a weekly basis that will be
included in the NIAMS safety officer report that is
submitted semi-annually. A serious AE (SAE) is any un-
toward medical occurrence that results in death, is life-
threatening, requires or prolongs hospitalization, causes
persistent or significant disability/incapacity, results in
congenital abnormalities, or represents other significant
hazards or potentially serious harm to research par-
ticipants or others. Study staff will report SAEs to the
project manager, study physician, and the principal in-
vestigator within 24 hours of notification. NIAMS will
be notified within 24 hours subsequent to notification of
the principal investigator.
Timeline
Recruitment for each of 10 waves takes 3 months with
an average of 37.2 participants/wave; an average of 12.4
participants are randomized/month for 30 months.
Randomization
A stratified block randomization with block size unknown
to investigators and staff ensures equal accrual to each
study arm. Prestratification balances pretrial BMI values
(20.0-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, 40.0-45.0 kg.m-2)
and gender, which could predict intervention effect and as-
sociations between secondary outcome variables.
Data management
Data are collected on hard copy forms and transformed
to an electronic database. We use a web-based manage-
ment system to assure integrity and validity. Dynamic
reports and periodic statistical analyses monitor quality.A participant-based inventory system tracks recruitment,
retention, adherence, and missing data from entry through
exit, close-out, and lock-down of final datasets. Our team
developed a similar database for the IDEA study.
Statistical considerations
Statistical analyses
All primary analyses are based on the intention-to-treat
method in which each participant is included in the ini-
tial randomization group regardless of adherence. START
stratification factors, baseline BMI, and gender are in-
cluded in all statistical models, so the analysis matches the
design, and the estimated variance is not biased. Assump-
tions are verified for all models, and appropriate transfor-
mations used when necessary.
Primary aim The primary aim is the treatment effect on
knee pain and maximal compressive force at 18 months.
These and all other repeated measures continuous out-
comes will be assessed using a mixed effects model in-
cluding time (6 and 18 months), treatment group, the
time × treatment interaction, and further adjusted for
gender, baseline BMI, and baseline values of the outcome
(i.e., baseline knee pain for knee pain model, baseline
compressive force for compressive force model). The
treatment effects at 18 months are tested by applying
contrast statements to the mixed model, and maximum-
likelihood techniques will be used to estimate param-
eters under the assumption of an AR(1) covariance
structure. Each primary outcome will be analyzed at
the Bonferroni-adjusted 0.025 level of significance, and
pairwise comparisons between intervention groups at
18 months will use a 0.0083 two-sided level of significance
(2 outcomes, 3 interventions) [88]. Preliminary analyses are
conducted to check the shape of the distributions and
variances between groups and as a function of the covari-
ates to ensure residuals are approximately normally dis-
tributed. Regression diagnostics and residual plots help
find appropriate transformations if necessary. In subse-
quent models, we will control for possible confounders,
including PF OA severity (none to moderate) and use of
medications, such as analgesics, NSAIDs, bisphosphonates,
and glucosamine/chondroitin sulfate. Because we ex-
clude subjects with severe PF OA and medication has
only modest efficacy in OA, we do not expect significant
confounding by these variables.
Secondary aims Standard repeated measures mixed
models (including adjustment variables as noted above)
are used for secondary aims at the 0.05 significance level,
with pairwise treatment group comparisons performed
at the 0.0167 significance level for testing 18 month ef-
fects. Short-term effects are determined by using contrast
statements comparing 6-month treatment effect means
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assessed at baseline and 18 months only (MoCa, DXA
measures, and Knee PA x-ray) will be compared using an
ANCOVA model for treatment effects adjusting for base-
line BMI, gender, and baseline values of the outcome.
As inflammatory marker distributions are often skewed,
data are log-transformed before analysis. The effect of the
interventions at 18 months is determined with repeated
measures mixed models and estimates obtained at each
visit. For ease of interpretation, transformed log means and
standard errors back to their original units are used.
Missing data If missing data are related to outcomes, our
results will be slightly biased. Our models include variables
from previous visits determined to predict loss to satisfy
Little and Rubin’s [89] conditions for data considered Miss-
ing at Random (MAR). If “informative censoring” occurs,
we will compare analyses using participants with complete
data, multiple imputations, or explicit modeling of the cen-
soring mechanism [90,91].
Sample-size calculations
Primary outcomes A total sample of 372 (124/group)
provide 80% statistical power to detect differences ≥17.6%
in pain and ≥9.6% in maximal compressive force at the
2-sided 0.0083 significance level with 80% retention
(2-sample t-test, Nquery Advisor). Standard deviations
for pain and maximal compressive force were obtained
from the START pilot (unpublished) and ADAPT [58,59]
which measured the same outcomes and used similar pa-
tient populations; with mean differences of 1.12 (18%)
and 657 N (20%), respectively.
Secondary outcomes Overall, our sample size provides a
moderate effect size of 0.46 with relevant detectable differ-
ences. ADAPT’s largest effect on WOMAC function was a
17% relative decrease. We are able to detect differences in
thigh-muscle volume smaller than 10%. Goopaster [92]
showed that after 12 months mean thigh-muscle attenu-
ation significantly decreased by 1.4 HU in a control group
but not in a physical activity group. With 6 more months
of physical activity, we expect to detect group differences
as small as 2.3 HU. A magnitude of 22% reduction in IL-6
is similar to reductions seen in clinical trials of statins and
other anti-inflammatory medications [93-98].
Discussion
Despite strong evidence for the potent effect of mechan-
ics on disease progression and symptoms [55,99], there
are few interventions that target mechanical load. One
such intervention is strength training. However, many
still believe that strength training for knee OA in gen-
eral, and high-intensity strength training specifically,
may exacerbate knee pain and be deleterious to jointstructure. It is critical to evaluate the potential benefit
(or harm) of commonly used therapeutic interventions
such as strength training. Due to conflicting data it is
unclear if an increase in the total joint reaction force oc-
curring with muscle strengthening contraction may ac-
tually accelerate the progression of structural changes
within the joint, rather than prevent it [100]. A longitu-
dinal study of 79 women with radiographic knee OA
found that the mean absolute quadriceps strength of
women with progressive OA (defined as worsening of the
Kellgren and Lawrence grade over 2.5 years) was about
9% lower than those with radiographically stable OA
[101]. In another observational study of 171 knee OA
participants over 18 months, Sharma and colleagues [21]
found that greater absolute quadriceps strength at base-
line increased the risk of disease progression (defined as
an increase in the grade of joint space narrowing in the
medial or lateral compartment) in people with malaligned
and lax knees (defined as >5° deviation from the mechan-
ical axis) but not in those with neutral alignment. Since
strength was not normalized for body mass, it is conceiv-
able that the stronger participants were heavier, since abso-
lute strength generally increases with body mass. More
recently, Amin et al. [102] found no relationship between
quadriceps strength and cartilage loss on MRI over 15 and
30 months anywhere except the lateral compartment
of the patellofemoral joint, where increased quadriceps
strength was protective against cartilage degeneration.
Mikesky et al. [13] demonstrated a trend (p = 0.09) that
strength training slowed joint space narrowing as mea-
sured on x-ray over 30 months in people with knee OA. It
is important to recognize that they did not do intense
training and did not elicit strength gains, just less strength
loss, so different effects might be found in our study. Given
the conflicting nature of the published literature and the
public health impact of both a negative and a positive find-
ing, the effects of strength training on pain, joint loading,
and structure are critical to delineate.
There are several limitations and risks to our study.
Our musculoskeletal model will estimate the knee joint
compressive and shear forces. The principal limitations
of most models are many simplifying assumptions about
joint properties and structures that do not account for
in-vivo symptoms and processes [39]. We have used our
model extensively [58-60,103], and while it only esti-
mates knee-joint biomechanics, the predictions for knee
muscle and joint forces compare favorably with those of
other predictive models, and are highly similar to mea-
sured forces from instrumented knee joint prostheses
[63,66,104,105]. PF OA may also confound results. The
symptoms in knee OA are frequently related to struc-
tural alterations in the PF joint, but despite great focus
on the PF joint this relationship is relatively weak
[106-108]. We will exclude people with severe PF OA
Messier et al. BMC Musculoskeletal Disorders 2013, 14:208 Page 12 of 15
http://www.biomedcentral.com/1471-2474/14/208(JSN = 3, OARSI scale) and control for severity (none to
moderate) in statistical analyses. Also measures of JSN
by plain films may not be sensitive enough to detect dif-
ferences in radiographic progression over 18 months un-
less the differences are large [109].
Risks to participants are small. Musculoskeletal injury
may occur as the result of the exercise intervention, but
during the strength-training portion of the recent IDEA
trial of 454 overweight or obese subjects with knee OA,
we had no serious injuries. We will include a blood pres-
sure safety alert trigger for this study. The absolute
contraindication to resistance training is set at greater
than 180/110 mmHg, and the relative contraindication
at above 160/100 mmHg. Bilateral volumetric measures
of thigh adipose tissue and skeletal muscle will use a
standard CT protocol. The thigh sequence is centered
on the mid-thigh and is about 33% of the expected ex-
posure of a clinical scan of this region. The average
amount of radiation a person will receive is low, 3 mSv
(range 1.5-6 mSv). This value can be comparable to the
U.S. average annual exposure from natural sources of
3 mSv and lower than the 7 mSv exposure of residents
of Denver. The risk is comparable to, or less than, other
risks encountered in daily life, such as driving or riding
in a motor vehicle [110].
Given the prevalence and impact of OA and the wide-
spread availability of strength training, assessing its effi-
cacy has immediate and vital clinical impact. Results of
this study will document accurately the effects of both
high-and low-intensity strength training on knee joint
pain, joint loads, inflammation, thigh composition, and
disease progression, and provide critically needed guid-
ance to clinicians who prescribe and oversee treatment
and prevention of OA-related complications.
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